Pharmaceutical Technology

SEPTEMBER 15, 2022

The document contains detailed information on the suppliers and their products, alongside contact details to aid your purchasing or hiring decisions.

Marketing 130

Marketing Manufacturing Generic Drugs Containment 130

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing. per-share deal valuing GBT at $5.4

Marketing 108

Marketing Sales Gene Editing Antibody 108

pharmaphorum

AUGUST 30, 2022

In July, Diurnal reported product sales of around £2.3 The Cardiff-based company’s pipeline also includes an oral testosterone in clinical trials for hypogonadism, as well as a modified-release levothyroxine for hypothyroidism and oligonucleotide-based therapy for Cushing’s disease in preclinical development.

Hormones 103

Hormones Sales Clinical Trials Clinical Trials 103

Pharmaceutical Technology

JULY 29, 2022

CAMP4’s CSO David Bumcrot PhD tells Pharmaceutical Technology that the company plans to see clinical trials go forward for their urea cycle disorder programs late next year. A nitrogen-binding drug, its global sales were $292m in 2021, as per GlobalData. Other treatments include sodium phenylbutyrate marketed as Buphenyl or Ammonaps.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

pharmaphorum

JULY 1, 2022

Sixth Street is paying the biotech $250 million upfront for a share of future royalties on Ayvakit and follow-up BLU-263, in a deal that also provides up to $660 million in credit facilities that can be used for business development. Blueprint is drawing $150 million of that straight away. billion if needed. billion if needed.

Business Development 52

Business Development Medicine Sales Marketing 52

pharmaphorum

NOVEMBER 21, 2022

The $36 per share, bolt-on deal helps to build Merck’s R&D portfolio as it tries to reduce the proportion of sales it makes from $17 billion-plus immuno-oncology blockbuster Keytruda (pembrolizumab), and build a franchise in haematology. The acquisition is expected to close in the first quarter of 2023.

RNA 57

RNA Clinical Trials Clinical Trials Business Development 57

pharmaphorum

SEPTEMBER 1, 2022

He was due to start at GSK this morning to lead the commercial aspects of its business development, seeking out late-stage deal opportunities as the pharma group tries to build up its pipeline and step up sales growth in the wake of its separation from consumer health business Haleon.

Business Development 102

Business Development Sales Trials Development 102

XTalks

APRIL 26, 2023

He began his career in business development and commercial strategy roles at Genentech. DermaSensor is currently not for sale in the United States. Clinical Performance of Novel Elastic Scattering Spectroscopy (ESS) in Detection of Skin Cancer: A Blinded, Prospective, Multi-Center Clinical Trial [Initial Results].

Life Science 52

Life Science Dermatology Clinical Trials Clinical Trials 52

pharmaphorum

JANUARY 26, 2021

From telehealth to digital trials, customer engagement to healthcare data, Healthware Group outlines the key trends that are expected to shake up digital health this year. Clinical trials get more and more digitalised. Aging in place’ becomes more commonplace. As such, reps will need to be reskilled.

Clinical Trials 141

Clinical Trials Clinical Trials Sales Life Science 141

pharmaphorum

MAY 18, 2022

billion in potential milestone payments plus royalties on sales. Merck is already pairing Keytruda with AstraZeneca and Daiichi Sankyo’s TROP2-directed ADC datopotamab deruxtecan in phase 3 trials to see if the combination can perform better than Keytruda alone in previously-untreated non-small cell lung cancer (NSCLC) patients.

Drugs 57

Drugs Antibody Licensing Licensing 57

pharmaphorum

JANUARY 12, 2023

The life sciences unit of Google parent Alphabet – which raised $1 billion back in September to fund its precision health agenda and business development activities, including possible acquisitions – said the move would allow it to streamline its operations.

Drug Delivery 65

Drug Delivery Life Science Production Engineer 65

Drug Discovery World

JUNE 29, 2023

Hatton will lead the Medical Analytics Practice vision, with responsibility for continuing to embed the latest digital innovations and advanced analytics practices across the business. Schumacher is an industry-experienced MD with many years of experience in conducting oncology clinical trials in an industry setting.

Drugs 52

Drugs Gene Therapy Development Clinical Trials 52

pharmaphorum

NOVEMBER 4, 2022

There is also a narrowing of its therapeutic range – exiting fibrosis and kidney disease in favour of greater efforts in immunology and oncology – and an increase in business development deals to strengthen Galapagos’ pipeline that will be fuelled by healthy cash reserves of around €4.3 Jyseleca has made €60.5

Business Development 52

Business Development Sales Regulation Drugs 52

The Pharma Data

AUGUST 3, 2021

Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). Product Sales Performance. Key results include: Total revenues increased 5% to $6.5

Sales 52

Sales Production Antibody Development 52

pharmaphorum

APRIL 25, 2022

Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . BehaVR will also receive tiered royalties from global sales of its DTx products.

Behavioural Health 104

Behavioural Health Production Clinical Trials Clinical Trials 104

pharmaphorum

SEPTEMBER 8, 2020

Both deals give Exelixis an exclusive option to license ADC candidates at the preclinical stage, before they are submitted for approval to start human trials, and can be extended if the parties agree. Last year, Exelixis paid $7.5 million in milestones.

Antibody 52

Antibody Licensing Licensing Drugs 52

The Pharma Data

NOVEMBER 5, 2020

net sales increased 11% to $1.32 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints. Third quarter 2020 EYLEA ® U.S. billion versus third quarter 2019. Total revenues (4). $.

Sales 52

Sales Production Manufacturing Antibody 52

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. The trial compared tirzepatide to insulin glargine in adults with type 2 diabetes and increased cardiovascular risk. Business Development/Other Developments.

Antibody 52

Antibody Sales Production Development 52

pharmaphorum

DECEMBER 16, 2022

Clinical trials technology company Saama has hired Dr Clinton White as its new chief delivery officer. Reagents supplier The Native Antigen Company has hired a new business development manager, Richard White , and senior product manager, Pardeep Sharda.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

The Pharma Data

OCTOBER 26, 2020

I am confident in our ability to advance our promising pipeline and clinical trials despite the challenging environment, and I believe that our leadership and track record of solid commercial execution will continue to drive long-term growth.”. Sales. Sales. Financial Summary.

Sales 40

Sales Vaccination Vaccine Production 40

pharmaphorum

AUGUST 17, 2021

A complaint filed by the US Securities and Exchange Commission (SEC) today accuses Matthew Panuwat, the then-head of business development at Medivation, of buying sizeable stock options in rival cancer-focused biotech InCyte Corp in the days before the merger went through in September 2016. Matthew Panuwat.

Business Development 52

Business Development Drug Trials Trials Development 52

pharmaphorum

OCTOBER 12, 2022

Now, we can grow our R&D more rapidly and hire more business development and marketing colleagues to extend our reach to customers,” Del Bourgo says. The capital increase is going to enable us to develop our business and our technology and to scale our platform.”.

Genome 103

Genome Genomics Medicine Development 103

pharmaphorum

FEBRUARY 11, 2022

Komodo’s Healthcare Map was previously used to help diagnose rare metastatic renal cell carcinoma patients, and Janssen Research & Development uses Komodo’s software for clinical trials for various therapeutic areas, including rare diseases. He oversees operations, including business development, sales and marketing, and people.

Life Science 103

Life Science Engineer Development Big Data 103

The Pharma Data

DECEMBER 20, 2020

Staatz Business Development & Strategy acted as corporate finance and transaction adviser on the deal. Cefepime/enmetazobactam has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled, double-blind, global Phase 3 trial.

Licensing 40

Licensing Licensing Life Science Manufacturing 40

The Pharma Data

JULY 29, 2021

Billion The 10% Operational Growth Excluding BNT162b2(1) in Second-Quarter 2021 Builds on the 6% Operational Growth Delivered by the Comparable Business in Second-Quarter 2020 Second-Quarter 2021 Reported Diluted EPS(2) of $0.98, Adjusted Diluted EPS(3) of $1.07 billion) Adjusted Cost of Sales(3) as a Percentage of Revenues 39.0%

Manufacturing 52

Manufacturing Sales Contract Manufacturing Vaccination 52

Pharmaceutical Technology

FEBRUARY 22, 2023

Additionally, Asceneuron is eligible for tiered double-digit royalties on ASN90’s global net sales. The OGA inhibitor was evaluated in three clinical studies including a double-blind, placebo-controlled, randomised Phase I trial and human positron emission tomography (PET) CNS target engagement study.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 27, 2021

We start to see concrete and promising development with regards to DTx reimbursement, which is a cornerstone to accelerate growth. Looking ahead, we expect to increase the investment in DTx as we see a progression in sales and a clearer picture emerges regarding the multiple routes to reimbursement.

Production 52

Production Marketing Sales Licensing 52

The Pharma Data

NOVEMBER 10, 2020

AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with business development to find suitable out-licensing solutions with other pharmaceutical companies. STOCKHOLM , Nov. [link]. Source link.

Development 40

Development Drugs Protein Research 40

pharmaphorum

SEPTEMBER 27, 2022

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics. Image by WikiImages from Pixabay.

Licensing 108

Licensing Licensing FDA Approval Clinical Trials 108

The Pharma Data

NOVEMBER 8, 2020

9, 2020 /PRNewswire/ — Solid 9M business performance despite COVID-19 and generic Aczone challenges: Net Sales €613.8 Ilumetri ® sales grew +125% year-on-year and Seysara ® showed Net Sales performance improvement quarter-on-quarter following clinically relevant FDA label improvement. MM (-3.7%; +4.3%

Dermatology 52

Dermatology Sales Marketing Production 52

The Pharma Data

OCTOBER 14, 2020

These factors include risks and uncertainties related to, among other things: the proposed settlement with governmental parties to resolve certain disputes relating to Acthar Gel; the possibility that such settlement will not be consummated and the risks and uncertainties related thereto, including the time and expense of continuing to litigate this (..)

Production 40

Production Branding Development Regulation 40

Delveinsight

SEPTEMBER 8, 2021

Pharma Consultants come up with various business strategies, technical or non-technical, management of quality control & testing, identifying relevant supplies and equipment, drug – design & development, and regulation of clinical trials. Market Assessment & Operational Sales.

Marketing 52

Marketing Production Sales Life Science 52

pharmaphorum

MARCH 31, 2021

Another recent change is the timelier release of scientific information; rather than holding on to clinical trial findings until the ‘perfect’ opportunity to present them at a major congress, 2020 increasingly saw pharmaceutical companies make data public in real time. Anna Bayley, director of business development, Caudex.

Clinical Trials 98

Clinical Trials Clinical Trials Business Development Trials 98

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

AUGUST 6, 2020

NEW YORK–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2020, which reflect strong product sales, continued advancement of the pipeline and robust operating performance. chairman and chief executive officer, Bristol Myers Squibb.

Production 52

Production Branding Marketing Licensing 52

Pharmaceutical Technology

JULY 23, 2008

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler. So what’s driving the growth?

Sales 130

Sales Marketing Drugs Licensing 130